Werewolf Therapeutics Inc logo

Werewolf Therapeutics Inc(HOWL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 55 days
PROFIT SINCE LAST BUY
+4.26% ▲
LAST CLOSE
$0.98
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HOWL

11/13/2026: HOWL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Werewolf Therapeutics Inc is a clinical-stage biopharmaceutical stock focused on engineering conditionally activated immune therapeutics for cancer treatment. Its primary strengths lie in its proprietary PREDATOR platform and clinical pipeline assets like WTX-124, which aim to reduce off-target toxicity. The core investment story centers on the potential of its masked cytokine and T-cell engager technologies to unlock safer, more effective tumor immunities. However, the company faces substantial execution, competitive, and valuation risks typical of pre-revenue biotechnology firms dependent on clinical trial results and external financing. This stock suits high-risk growth investors willing to monitor binary clinical readouts and ongoing capital requirements.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high-risk, high-reward exposure to early-stage clinical immunotherapy innovation.
Momentum investorStrong fit while signal remains positiveShort-term momentum can spike around clinical data readouts or partnership announcements.
Value investorWeak fitThe company lacks commercial product revenue and consistent positive earnings.
Dividend investorWeak fitNo dividends are paid as capital is reinvested entirely into research and development.
Low-risk investorWeak fitHigh share price volatility and binary clinical trial outcomes expose investors to substantial downside.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stock prices swing sharply based on clinical trial updates and market sentiment.
Valuation riskHighValuation is heavily speculative due to the pre-revenue clinical status of the pipeline.
Competition risk (immuno-oncology platform competition)Medium / highNumerous competitors are pursuing similar cytokine-masking and T-cell engager strategies.
Business qualityMediumThe science is differentiated, but commercial viability remains unproven.
Dividend incomeLow / noneThe company does not distribute income or dividends to shareholders.
Execution riskHighSuccess depends entirely on steering clinical candidates successfully through complex trials and regulatory reviews.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 47.64M USD
Price to earnings Ratio -
1Y Target Price 7
Price to earnings Ratio -
1Y Target Price 7
Volume (30-day avg) 357.4K shares
Beta 0.55
52 Weeks Range 0.27 - 1.20
Updated Date 11/15/2026
52 Weeks Range 0.27 - 1.20
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.73

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -40.78%
Avg. Invested days 23
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HOWL receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
HOWL has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+13.7%) is partially offset by soft cash generation (FCF margin 0.0%), negative revenue growth (-100.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
HOWL's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is HOWL's strongest growth driver at +13.7% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (-100.0%, negative) and free-cash-flow growth (-6.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 42.3% and approximately 93.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.62% supports management-shareholder alignment.

Top 5 Institutional Investors

RA Capital Management, LLC 4.91%
Balyasny Asset Management LLC 3.68%
Vanguard Capital Management, LLC 2.51%
Lynx1 Capital Management, LP 1.35%
Sphera Funds Management Ltd. 1.29%

Unit Economics (Per $1K Revenue)

★★★★★
HOWL generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
HOWL has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical Collaborations and GrantsUpfront license fees, milestone payments, and research funding from strategic pharmaceutical partnerships.The company is pre-commercial and does not yet sell commercial drugs, relying instead on collaboration agreements and capital raises.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 25.64M
Price to Sales(TTM) 2.27
Enterprise Value 25.64M
Price to Sales(TTM) 2.27
Enterprise Value to Revenue 1.22
Enterprise Value to EBITDA 0.57
Shares Outstanding 48.60M
Shares Floating 45.38M
Shares Outstanding 48.60M
Shares Floating 45.38M
Percent Insiders 6.62
Percent Institutions 42.34

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.